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bstract
ackground: Previous in vitro studies indicated that Atazanavir (ATV) has a distinct resistance profile than other protease inhibitors (PIs).
n treatment-experienced patients ATV resistance is characterised by the accumulation of at least four mutations among those that confer
ross-resistance to the PIs.
bjective: We studied the evolution of PIs resistance mutations in 10 HAART-failed patients undergoing ATV enrolled in an early access
rogram.
tudy design: Virus genotypic resistance was determined from plasma collected at baseline and during treatment. HIV-RNA was extracted
nd the pol region amplified and sequenced. Genotypic data were used to determine drug susceptibility. Phylogenetic analysis was performed.
esults: At baseline, genotypic data showed cross-resistance patterns to approved PIs in 6 patients. In two of these subjects new mutations
I54V and A71V) conferring cross-resistance emerged after 3 months of therapy. The I50L mutation was evidenced in one subject after 12
onths of treatment. The “virtual” phenotype analysis mirrored the resistance profiles to ATV and other PIs and evidenced differences withipranavir and darunavir.
onclusion: Genotype evolution within the protease region did not emerge at significant levels during salvage therapy of multidrug-experienced
atients. ATV exhibited certain/same virologic effect on the majority of our patients.
2007 Elsevier B.V. All rights reserved.
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. Introduction
Atazanavir (ATV) is a novel azapeptide protease inhibitor.
t has recently been approved by the FDA/EMEA for the treat-
ent of HIV infection, and its pharmacokinetic profile makes
t the first PI that can be administered once daily (Robinson
t al., 2000). ATV can be used in combination with other
rugs as first-line treatment or as salvage therapy (Musial et
l., 2004; De Mendoza et al., 2006).
ATV offers some important advantages, as favourable
etabolic toxicity profile (lipid and glucidic metabolism)
∗ Corresponding author. Tel.: +39 02 39042668; fax: +39 02 50319758.
E-mail address: stefano.rusconi@unimi.it (S. Rusconi).
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oi:10.1016/j.jcv.2007.10.003Fuster and Clotet, 2005; Johnson et al., 2006a,b; Noor et
l., 2006; Mallolas et al., 2007).
The mutation I50L appeared to decrease affinity of the
nzyme for ATV while increasing the affinity for other PI
Yanchunas et al., 2005). Eight PI mutations (10F/I/V, 16E,
3I/F/V, 46I/L, 60E, 64V, 85V and 90M) were described to
ffect the clinical response to ATV/rtv. All patients showed
virologic response to ATV when 2 or less mutations were
resent, independently of the background regimen (Vora et
l., 2006).Genotypic analysis of phenotypically selected resistant
iruses to ATV showed presence of amino acid substitu-
ion in the viral protease (A71V, N88S, I84V) and based
n new data minor mutations were added to ATV (with or
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ithout boosting with low-dose ritonavir) (Johnson et al.,
006a,b).
The aim of this study was to evaluate the evolution of
esistance associated mutations located in the region of the
rotease enzyme, after administration of ATV.
. Materials and methods
Ten HIV-1 infected patients in HAART therapy followed
p in our Institute were enrolled in this study. At screen-
ng, nine patients were failing their current regimen and one
ad pharmacological intolerance, with serious associated side
ffects. One out of nine had cardiovascular risk factors in his
linical history.
All patients gave informed consent to participate to this
pproved study, by the Institutional Review Board of Luigi
acco Hospital, University of Milan.
Genotype of viral isolates was performed from plasma
amples at the first drug administration time (M0) and at 3, 6, 9
nd 12 months, when available. HIV-RNA was extracted and
he pol region was amplified by nested RT-PCR, as previously
escribed (Najera et al., 1995; Rusconi et al., 1997, 2000;
rusano et al., 1998).
The obtained genotypic profiles were used for the phylo-
enetic analysis. Such as to evaluate the evolution of different
iral strains during the treatment. The consensus sequence of
IV-1 subtype A, derived from Los Alamos data bank, was
sed as reference clade of the phylogenetic tree. We chose
o root the tree according to a strain which was not close
o the sequences analysed: as all the sequences belonged to
ubtype B, a subtype A was chosen as root. Other subtype B
equences from the same laboratory were used as control for
ontamination. Sequences alignment of gene fragments was
one automatically by Clustal X program 1.8 version.
ATV viral susceptibility data were obtained by Virtual
henotype using VircoNETTM 1.6.7 version, that compare
eal geno-phenotypic data to consensus sequences deposited
n the Virco data bank (Virco BVBA, Mechelen, Belgium).
Genotypic susceptibility scores (GSS) and viral drug sus-
eptibility were calculated by a computer program (HIVdb,
tanford University, CA, USA), that uses available muta-
ion scoring tables based on published literature (Rhee et al.,
003). The GSS was calculated by summing up scores of
ifferent drugs (Kantor et al., 2004).
The nucleotide sequences have been submitted to Gen-
ank: accession numbers EF526180-EF526209.
. Results
.1. Patients baseline featuresData are summarized in Table 1. To 8 of 10 patients
as assigned a lower genotypic susceptibility score (<1.75),
hereas 2 of 10 showed a higher GSS. The median CD4+ Ta
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Fig. 1. Neighbor-joining phylogenetic tree of pol sequences. Kimura-2
parameter. transition/transversion ratio: 2.00. Showing bootstrap values
>75% only. Consensus of subtype A strains (A1) was used as an outgroop.
Laboratory HIV-1 strain such as HXB2 and patients’ sequences from the
Sacco Hospital (A M0 and M3, B M0 and M3, C M0 and M4) were used as
c
c
t
s
T
l
e
w
l
o
s
p56 B. Vergani et al. / Journal of C
ell count at start of study was 94.50/l (IQR: 66.00–203.00)
nd the median plasma HIV-1 RNA was 41,526.50 copies/ml
IQR: 1545.00–115,922.00).
.2. Viral load in Atazanavir-treated patients
In patients ATV3 and ATV10, there was a constant reduc-
ion over time of 3 and 1.5 log (<50 cp/ml in ATV10),
espectively. Patient ATV1 also showed a decrease of about
.5 log, followed by a slight increase at M12. Viral load in
atients ATV2, ATV5, ATV6 and ATV7 remained substan-
ially unchanged. Patients ATV4 and ATV9 showed an initial
eduction followed by an increase in HIV-RNA, whereas the
iral load of patient ATV8 increased since Atazanavir was
tarted. In patient ATV9 the detection of HIV-RNA at M12
as followed by a constant viral suppression.
.3. Genotypic analysis
The genotypic analysis revealed mutations in viral pro-
ease: some of these emerged after starting Atazanavir,
ncluding some major mutations such as I54V and I54A,
73S, and N88S, and some minor mutations, such as L33F
nd A71V. Some others did not appear in different positions
uch as K20K/M, M36M/I, I47I/V and N88N/S. Genotype
ata are shown in Table 2
.
The resistance profile of the virus in patient ATV1 at M12
howed appearance of mutation I50L, which is characteris-
ic of PI-naive patients taking ATV, but rare in pretreated
atients. In patient ATV7, the mutation G48V was no longer
etected.
The resistance profiles of patients ATV9 and ATV10 were
nly evaluated at M0 because their viral load decreased to
50 cp/ml at the subsequent time points (M3 and M6 in the
ase of ATV9, and M6 and M12 in the case of ATV10) and
mplification of the samples failed.
.4. Phenotypic analysis
Table 2 shows the data related to the phenotypic analy-
is made using Virtual Phenotype. Patients ATV1 and ATV8
howed likely resistance to Atazanavir throughout the obser-
ation period, whereas patient ATV2 developed resistance
ver time. Patients ATV3, ATV4 and ATV6 maintained a
table response to the drug. Finally, the resistance profiles
f patients ATV5 and ATV7 improved over time showing a
ecrease in the IC50 fold-change. Viral phenotype of ATV9
nd ATV10 was not determined, due to negative cell culture.
.5. Phylogenetic analysisTo explore the genetic diversity of HIV-1 we analyzed
ll available sequences. Patients ATV9 and ATV10 were
ot included in the phylogenetic analysis as their viral load
ropped at <50 cp/ml after starting the ATV regimen.
4
bontrols. The distance between two individual sequences can be derived by
omparing the length of the horizontal branches separating the sequences to
he scale bar.
All patients were infected with subtype B strains and
equences showed the expected patient-specific clustering.
he temporal analysis of pol sequences showed limited evo-
ution between the first and the last available sequence for
ach patient suggesting that the overall genetic evolution
as extremely limited for these patients. The sequences at
ater time points did not accumulate a significant number
f mutations and diverge a lot from the baseline sequences,
uggesting that there may be a bias against newly emerging
rotease variants (Fig. 1).. Discussion
We studied a cohort of HIV-positive patients characterised
y multiple therapeutic failures or pharmacological intol-
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Table 2
Genotypic resistance profiles in the plasma compartment and ATV, TPV, DRV Virtual Phenotype
PTS Time Genotype profile
ATV1 M0 L10F, L24I, L33F, M46I, I54V, L63P, A71V, G73S, V77I, V82A
M3 L10F, L24I, L33F, M46I, I54V, L63P, A71V, G73S, V77I, V82A
M6 L10F, L24I, L33F, M46I, I54V, L63P, A71V, G73S, V77I, V82A, N88N/S
M12 L10F, L24I, L33F, M46I, I50L, I54V, L63P, A71V, G73S, V77I, V82A
ATV2 M0 L10F, K20R, L33F, M36I, I54V, L63P, A71V, V82A, I84V, L90M
M6 L10F, K20R, L33F, I54V, L63P, A71V, G73S, I84V, L90M
M12 K20R, L33F, M36I, I54V, L63P, A71V, G73S, V82A, I84V, L90M
ATV3 M0 L63P
M3 L63P
M6 M36M/I
M12 L63P
ATV4 M0 L10I, M36I, L63P, A71V, V82A, I84V, L90M
M3 L10I, M36I, I54V, L63P, A71V, V82A, I84V, L90M
M6 L10L/I, K20K/M M36M/I, I54V, L63P, A71V, V82A, I84I/V, L90M
M12 L10I, M36I, I54V, L63P, A71V, V82T, I84V, L90M
ATV5 M0 L10I, M46L, I54V, L63P, V77I, I84V, L90M
M3 L10I, M46L, I54V, L63P, A71V, V77I, I84V, L90M
M6 L10I, M46L, I54V, L63P, A71V, G73S, V77I, I84V, L90M
M12 L10I, L33F, M46L, I54A, L63P, A71V, V77I, I84V, L90M
ATV6 M0 L10I, K20R, L33F, M36I, I54V, L63P, A71V, G73S, V82A, L90M
M6 L10I, K20R, L33L/F, M36I, I54V, L63P, A71V, G73G/S, V82A, L90M
M9 L10I, K20R, L33F, M36I, I54V, L63P, A71V, G73S, V82A, L90M
ATV7 M0 L10I, M46L, G48V, I54V, L63P, A71T, V82A
M3 L10I, M46L, G48V, I54V, L63P, A71T, V82A
M12 L10I, M46L, I54V, L63P, A71T, V82A
ATV8 M0 L10I, K20R, V32I, L33F, M36I, I47V, L63P, A71V, V82T, L90M
M6 L10I, K20R, V32I, L33F, M36I, I47I/V, L63P, A71V, V82T, L90M
M12 L10I, K20R, V32I, L33F, M36I, I54A, L63P, A71V, V82T, L90M
ATV9 M0 L10F, K20R, V32I, M36I, M46I, I47V, I54M, L63P, A71V, V82A, L90M
M3 /
M6 /
ATV10 M0 L10I, L63P, V77I
M6 /
M12 /
ATV FC
(IC50)
ATV CCO1-CCO2
interpretation
TPV FC
(IC50)
TPV CCO1-CCO2
interpretation
DRV FC
(IC50)
DRV CCO1-CCO2
interpretation
13.4 Partially resistant 0.5 Susceptible 1.6 Susceptible
21.2 Partially resistant 0.7 Susceptible 1.2 Susceptible
54.0 Resistant 0.6 Susceptible 0.9 Susceptible
112.1 Resistant 0.5 Susceptible 0.6 Susceptible
24.7 Partially resistant 4.2 Partially resistant 4.7 Partially resistant
54.5 Resistant 4.9 Partially resistant 7.6 Partially resistant
32.6 Partially resistant 7.0 Resistant 4.0 Partially resistant
0.7 Susceptible 0.9 Susceptible 0.6 Susceptible
0.6 Susceptible 0.9 Susceptible 0.6 Susceptible
0.5 Susceptible 0.9 Susceptible 0.5 Susceptible
0.5 Susceptible 0.9 Susceptible 0.6 Susceptible
31.7 Partially resistant 5.5 Resistant 6.7 Partially resistant
22.8 Partially resistant 5.6 Resistant 6.6 Partially resistant
11.0 Partially resistant 2.2 Partially resistant 1.9 Susceptible
36.6 Resistant 12.0 Resistant 5.1 Partially resistant
24.7 Partially resistant 3.1 Susceptible 1.3 Susceptible
15.8 Partially resistant 3.4 Susceptible 1.5 Susceptible
31.0 Partially resistant 2.3 Susceptible 1.8 Susceptible
38.7 Resistant 28.9 Resistant 5.6 Partially resistant
143.4 Resistant 2.1 Partially resistant 1.8 Susceptible
18.8 Partially resistant 1.1 Susceptible 0.7 Susceptible
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Table 2 (Continued )
ATV FC
(IC50)
ATV CCO1-CCO2
interpretation
TPV FC
(IC50)
TPV CCO1-CCO2
interpretation
DRV FC
(IC50)
DRV CCO1-CCO2
interpretation
96.1 Resistant 2.1 Partially resistant 1.8 Susceptible
26.6 Partially resistant 0.6 Susceptible 0.7 Susceptible
11.7 Partially resistant 0.5 Susceptible 0.7 Susceptible
4.1 Partially resistant 1.4 Partially resistant 0.8 Susceptible
37.8 Resistant 19.6 Resistant 4.1 Partially resistant
27.1 Partially resistant 16.6 Resistant 4.2 Partially resistant
37.7 Resistant 18.6 Resistant 4.1 Partially resistant
14.6 Partially resistant 0.8 Susceptible 5.4 Partially resistant
n.a. – n.a. – n.a. –
n.a. – n.a. – n.a. –
0.5 Susceptible 0.7 Susceptible 0.5 Susceptible
n.a. – n.a. – n.a. –
n.a. – n.a – n.a –
Notes: PTS, patients; M0, baseline; M3, 3rd month; M6, 6th month; M9, 9th month; M12, 12th month. Bold character: mutations not present at t0; italic character:
mutations differing only in terms of the highlighted amino acid; /: not evaluable (HIV-RNA <50 cp/ml). FC in IC50 (fold-change inhibitory concentration 50%):
calculated with reference to a wild-type virus, according the Virconet explanation; n.a.: not available. CCO: clinical cut-off values; CCO1: baseline FC in IC50,
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ausceptible which the virologic response to a drug is expected to be simila
hich most virologic response to the drug is expected to be lost due to res
tipranavir) during the 10th month of treatment.
rance and unbalanced lipid and glucidic profile. Our aim
as to analyse the evolution of the mutations located in the
egion of the protease enzyme that lead to resistance to PIs
ollowing the administration of Atazanavir. Previous studies
howed that baseline phenotypic susceptibility had a role on
he response to PI treatment (Naeger and Struble, 2006).
The genotypic resistance analysis (Table 2) revealed only
ew new mutations (I50L, I54V, A71V, G73S and N88N/S)
onferring resistance to Atazanavir. These mutations do not
nduce cross-resistance to other protease inhibitors (except
inor mutation G73S that confers resistance to darunavir
oosted with ritonavir). Two of 10 patients had a similar FC
rofile, whereas 8 of 10 showed a higher sensitivity of TPV
nd DRV compared to ATV. This was more evident for the last
ompound since there was less concordance between ATV-
elated and DRV-related mutations in our samples. In the
uest of the ideal antiretroviral therapy regimen, there is an
merging issue regarding the sequentiability from ATV to
PV or DRV.
In particular, patient ATV1 developed the N88N/S muta-
ion over time, and the I50L mutation at M12. This
ubstitution conferring resistance to Atazanavir is character-
stic of PI-naive patients, but is very rare in pretreated patients
Noor et al., 2006). Comparison of viruses bearing I50L with
hose bearing I50V revealed specific resistance to Atazanavir
nd Amprenavir (APV), respectively, with no evidence of
ross-resistance (Colonno et al., 2004; Weinheimer et al.,
005). The HIV-protease enzyme from multi-experienced
ubjects is already largely mutated and therefore consider-
bly stiff, one of the reasons for the rarity of mutation I50L in
ubjects who have accumulated multiple resistances to PIs.
urthermore, the enzyme itself would not benefit from the
cquisition of a new mutation in position 50, a finding that
eems to correlate well with the patient’s phenotypic suscep-
ibility (Table 2). The trend of viral load also highlighted an
A
Kof a wild-type virus (loss of 20% of response); CCO2: FC in IC50, above
(loss of 80% of response). ATV5: Atazanavir was replaced by another PI
ncrease in replication as from M6, when mutation N88N/S
ppeared and was followed by I50L.
Moreover, ATV5 analysis of genotypic resistances high-
ighted the loss of mutation G73S at M6 and appearance
f L33F. This was probably due to the fact that the patient
topped taking ATV in the 10th month of treatment (i.e. 2
onths before the M12 sample) and switched to a different
I (TPV) (Schapiro et al., 2005; The RESIST 2 and RESIST
Study Teams, 2006), as mutation L33F is known as TPV-
nduced modification (Valdez et al., 2005).
The infectivity of viruses was tested: there was a constant
ecrease in viral titration values over time.
Our data confirm that ATV should be boosted when used
n multidrug-experienced patients, nevertheless several stud-
es demonstrated a favourable lipid profile of boosted-ATV
oth at 48 and 96 weeks (Johnson et al., 2006a,b; Mallolas
t al., 2007).
Finally, phylogenetic analysis of the protease sequences
emonstrated a limited evolution of the viral variants during
TV therapy: it is possible that occurrence of variants resis-
ant to ATV requires a very high price in terms of fitness, as
he lower replicative capacity of the strains harbouring I50L,
73S and N88S seems to suggest.
In conclusion, ATV exhibited a certain virologic effect
n the majority of our patients, thus subjects with multiple
herapeutic failures with or without an increased cardiac risk
ad taken advantage from ATV-containing therapies with a
inimal evolutionary cost. In this clinical setting, ATV use
ould be advantageous in multiple failed subjects without
ccelerating HIV-1 evolution.cknowledgements
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